By: IPP Bureau
Last updated : May 18, 2026 6:55 am
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Akums Drugs & Pharmaceuticals Ltd. reported a strong improvement in profitability for the fourth quarter and full year ended March 31, 2026, driven by robust growth in its core CDMO business, improved operating efficiencies and continued international expansion.
For Q4 FY26, the company posted operating revenue of Rs. 1,158 crore, registering a 9.7% year-on-year increase compared to Rs. 1,056 crore in the corresponding quarter last year. Adjusted EBITDA rose sharply by 61.6% YoY to Rs. 152 crore, while EBITDA margin improved significantly to 13.1% from 8.9%.
Adjusted Profit After Tax (PAT) more than doubled to Rs. 83 crore from Rs. 35 crore in Q4 FY25, reflecting a 135% year-on-year growth. PAT margin improved to 7% compared to 3.3% in the same period last year.
On a full-year basis, Akums reported FY26 operating revenue of Rs. 4,359 crore, up 5.9% YoY, while adjusted EBITDA increased 13.3% to Rs. 522 crore. Adjusted PAT for the year grew 27.3% to Rs. 276 crore.
The company’s CDMO business remained the primary growth engine during the quarter. CDMO revenue increased to Rs. 952 crore from Rs. 840 crore in Q4 FY25, while EBITDA from the segment rose 54.9% year-on-year to Rs. 137 crore. EBITDA margin for the segment expanded to 14.4% from 10.6%, supported by stronger customer engagement, improved capacity utilisation and focused execution.
Commenting on the performance, Sanjeev Jain said, “FY26 has been a year of steady progress for Akums. We delivered healthy growth in revenue and profitability while continuing to build capabilities for the long term. Our regulatory milestones, international developments and strong domestic performance reflect our focus on building Akums as a global pharmaceutical company and a trusted partner for our clients.”
Sandeep Jain added, “The Q4FY26 and full year performance showed improvement across key operational parameters. Our CDMO business continued to perform well as we remain focused on better capacity utilisation, cost discipline and future growth. We are working on multiple digitization and automation initiatives which will deliver long-term value for the organization.”
Akums also made notable progress in strengthening its global presence during FY26. The company completed its first commercial supply of formulations to Europe, secured EU GMP certifications for its Oral Solids and Oral Liquids facilities, and received its first UK MHRA approval for Rivaroxaban. Its injectable facility also received Brazil ANVISA approval, while the groundbreaking ceremony for its Zambia pharmaceutical plant marked another milestone in its international expansion strategy.
The Domestic Branded Formulations business remained stable during the quarter, reporting revenue of Rs. 102 crore, while full-year revenue for the segment rose 2.9% to Rs. 446 crore. EBITDA for the segment increased 17% year-on-year to Rs. 90 crore during FY26.
The International Branded Formulations business reported quarterly revenue of Rs. 36 crore, while annual revenue remained steady at Rs. 143 crore. However, EBITDA for the segment increased 32.3% year-on-year to Rs. 36 crore, indicating improving operational efficiency.
Akums’ Trade Generics business also showed signs of recovery, turning EBITDA positive at Rs. 1.4 crore during Q4 FY26. For the full year, EBITDA losses in the segment reduced sharply to Rs. 10 crore from Rs. 28 crore in FY25.
Despite the overall positive performance, the API business continued to remain under pressure due to pricing challenges. API revenue declined to Rs. 41 crore in Q4 FY26 from Rs. 50 crore a year ago, with the segment reporting an operating loss of Rs. 12 crore. However, the company stated that it remains focused on portfolio optimisation, cost discipline and operational efficiencies to support long-term sustainable growth.
The Board of Directors also recommended a final dividend of Rs. 1 per equity share and a special dividend of Rs. 2 per equity share for FY26.